Gemcitabine and Carboplatin for Advanced Bladder Cancer
Author Information
Author(s): Xu Nong, Zhang Xiao Chen, Xiong Jian Ping, Fang Wei Jia, Yu Lan Fang, Qian Jiong, Zhang Ling
Primary Institution: The First Affiliated Hospital, School of Medicine, Zhejiang University
Hypothesis
The study aims to evaluate the activity and tolerability of gemcitabine plus carboplatin as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium.
Conclusion
The combination of gemcitabine plus carboplatin is effective in treating advanced transitional cell carcinoma with manageable toxicity.
Supporting Evidence
- The overall response rate was 46.2%, with 10.3% complete responses and 35.9% partial responses.
- Median progression-free survival was 7.5 months and median overall survival was 13.6 months.
- Grade 3/4 neutropenia occurred in 36.6% of patients, indicating significant hematological toxicity.
Takeaway
This study tested a new medicine combination for bladder cancer and found it works well without causing too many side effects.
Methodology
Patients received gemcitabine and carboplatin in a specific schedule and were monitored for response and side effects.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study was limited to a single-arm design and included only Chinese patients.
Participant Demographics
Median age was 64.5 years, with 75.6% male and 24.4% female participants.
Statistical Information
P-Value
p<0.0000
Confidence Interval
95% CI: 32–65%
Statistical Significance
p<0.0000
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website